Athersys Company Profile (NASDAQ:ATHX)

About Athersys (NASDAQ:ATHX)

Athersys logoAthersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ATHX
  • CUSIP: N/A
  • Web: www.athersys.com
Capitalization:
  • Market Cap: $171.43 million
  • Outstanding Shares: 111,316,000
Average Prices:
  • 50 Day Moving Avg: $1.46
  • 200 Day Moving Avg: $1.40
  • 52 Week Range: $1.02 - $2.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.47
  • P/E Growth: -0.21
Sales & Book Value:
  • Annual Revenue: $3.36 million
  • Price / Sales: 51.68
  • Book Value: $0.26 per share
  • Price / Book: 6.00
Profitability:
  • EBIDTA: ($28,340,000.00)
  • Net Margins: -765.65%
  • Return on Equity: -135.04%
  • Return on Assets: -95.38%
Debt:
  • Current Ratio: 4.15%
  • Quick Ratio: 4.15%
Misc:
  • Average Volume: 1.34 million shs.
  • Beta: -0.13
  • Short Ratio: 9.7
 

Frequently Asked Questions for Athersys (NASDAQ:ATHX)

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) announced its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. The business earned $1.50 million during the quarter, compared to the consensus estimate of $0.45 million. Athersys had a negative return on equity of 135.04% and a negative net margin of 765.65%. The company's quarterly revenue was down 90.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.06 EPS. View Athersys' Earnings History.

When will Athersys make its next earnings announcement?

Athersys is scheduled to release their next quarterly earnings announcement on Monday, August, 7th 2017. View Earnings Estimates for Athersys.

Where is Athersys' stock going? Where will Athersys' stock price be in 2017?

3 equities research analysts have issued 1 year target prices for Athersys' stock. Their predictions range from $7.00 to $9.00. On average, they anticipate Athersys' share price to reach $8.00 in the next twelve months. View Analyst Ratings for Athersys.

What are analysts saying about Athersys stock?

Here are some recent quotes from research analysts about Athersys stock:

  • 1. Maxim Group analysts commented, "Athersys spent $5.6M in the quarter and ended the period with $32M in cash at the end of the period (which includes $21M from a capital raise in February). This capital should support the company for the next year. Lonza: Athersys manufacturing partner completed a manufacturing review that has now paved the way for product to be supplied for pivotal trials (including Healio’s Treasure trial). Partnering: Looking for partners now for MultiStem." (5/10/2017)
  • 2. According to Zacks Investment Research, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. " (3/14/2017)
  • 3. Needham & Company LLC analysts commented, "Athersys is developing MultiStem, an off-the-shelf cell therapy that promotes tissue repair. The lead indication is ischemic stroke. Existing stroke treatments, which focus on removing the offending blood clot, can only be used in a short window of time, but MultiStem has shown efficacy in a longer time window (24-36 hours) and can thus address far more patients. Athersys' Japanese partner Healios will start a 220-patient pivotal trial shortly. Data is expected in mid-2018. While there is some controversy around the Phase II data, we believe the trial has a favorable risk:reward in what we see as a blockbuster opportunity. Initiate at Buy with a $7 price target." (2/7/2017)

Who are some of Athersys' key competitors?

Who are Athersys' key executives?

Athersys' management team includes the folowing people:

  • Gil Van Bokkelen Ph.D., Chairman of the Board, Chief Executive Officer
  • William Lehmann Jr, President, Chief Operating Officer
  • John J. Harrington Ph.D., Executive Vice President, Chief Scientific Officer, Director
  • Robert J. Deans Ph.D., Executive Vice President - Regenerative Medicine
  • Laura K. Campbell CPA, Vice President - Finance
  • Lee E. Babiss Ph.D., Lead Independent Director
  • Ismail Kola, Independent Director
  • Lorin Jeffry Randall, Independent Director
  • Jack L. Wyszomierski, Independent Director

Who owns Athersys stock?

Athersys' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.00%), Geode Capital Management LLC (0.00%), Old Mutual Global Investors UK Ltd. (0.32%), TIAA CREF Investment Management LLC (0.00%), Bank of New York Mellon Corp (0.24%) and Goldman Sachs Group Inc. (0.22%). Company insiders that own Athersys stock include Bokkelen Gil Van, Ismail Kola, John J Harrington, Laura K Campbell, William Lehmann Jr and William Lehmann, Jr. View Institutional Ownership Trends for Athersys.

Who sold Athersys stock? Who is selling Athersys stock?

Athersys' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, NEXT Financial Group Inc and TIAA CREF Investment Management LLC. Company insiders that have sold Athersys stock in the last year include John J Harrington and William Lehmann Jr. View Insider Buying and Selling for Athersys.

Who bought Athersys stock? Who is buying Athersys stock?

Athersys' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Old Mutual Global Investors UK Ltd., Geode Capital Management LLC, Goldman Sachs Group Inc., FNY Partners Fund LP, TFS Capital LLC, Bank of New York Mellon Corp and Teachers Advisors LLC. Company insiders that have bought Athersys stock in the last two years include Ismail Kola and Laura K Campbell. View Insider Buying and Selling for Athersys.

How do I buy Athersys stock?

Shares of Athersys can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Athersys' stock price today?

One share of Athersys stock can currently be purchased for approximately $1.56.


MarketBeat Community Rating for Athersys (NASDAQ ATHX)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  92 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  134
MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Athersys (NASDAQ:ATHX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.00 (412.82% upside)

Analysts' Ratings History for Athersys (NASDAQ:ATHX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/16/2017Maxim GroupSet Price TargetBuy$9.00MediumView Rating Details
3/28/2017William BlairReiterated RatingOutperformHighView Rating Details
2/7/2017Needham & Company LLCInitiated CoverageBuy$7.00N/AView Rating Details
1/10/2016WBB SecuritiesReiterated RatingBuy$9.00N/AView Rating Details
7/10/2015Piper Jaffray CompaniesDowngradeOverweight -> HoldN/AView Rating Details
(Data available from 6/29/2015 forward)

Earnings

Earnings History for Athersys (NASDAQ:ATHX)
Earnings by Quarter for Athersys (NASDAQ:ATHX)
Earnings History by Quarter for Athersys (NASDAQ ATHX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017        
5/9/2017Q1 2017($0.07)($0.06)$0.45 million$1.50 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.08)($0.10)$0.45 million$0.98 millionViewListenView Earnings Details
11/9/2016Q3 2016($0.10)($0.07)$0.60 million$0.31 millionViewListenView Earnings Details
8/9/2016Q216($0.10)($0.08)$0.32 million$0.60 millionViewN/AView Earnings Details
5/5/2016Q1($0.08)$0.06$1.85 million$15.45 millionViewN/AView Earnings Details
3/10/2016Q4($0.09)$0.04$3.72 million$10.61 millionViewListenView Earnings Details
11/5/2015Q315($0.07)($0.08)$1.75 million$0.40 millionViewListenView Earnings Details
8/6/2015Q2($0.08)$0.02$2.66 million$0.22 millionViewN/AView Earnings Details
5/11/2015Q115($0.07)($0.16)$2.01 million$0.73 millionViewListenView Earnings Details
3/12/2015Q414($0.09)($0.08)$0.50 million$0.24 millionViewN/AView Earnings Details
11/10/2014Q314($0.09)($0.11)$0.54 million$0.29 millionViewN/AView Earnings Details
8/11/2014Q214($0.09)($0.06)$0.70 million$0.40 millionViewN/AView Earnings Details
5/8/2014Q114($0.10)($0.09)$0.66 million$0.71 millionViewN/AView Earnings Details
3/13/2014Q413($0.11)($0.15)$1.81 million$0.92 millionViewN/AView Earnings Details
11/14/2013Q3($0.12)($0.10)$0.49 million$0.62 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.12)($0.11)$390.00 million$0.57 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.11)($0.18)$1.58 million$0.33 millionViewN/AView Earnings Details
11/8/2012Q312($0.13)($0.12)$2.51 million$1.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Athersys (NASDAQ:ATHX)
2017 EPS Consensus Estimate: ($0.27)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.07)($0.07)($0.07)
Q2 20172($0.07)($0.06)($0.07)
Q3 20172($0.07)($0.06)($0.07)
Q4 20172($0.07)($0.06)($0.07)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Athersys (NASDAQ:ATHX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Athersys (NASDAQ:ATHX)
Insider Ownership Percentage: 10.90%
Institutional Ownership Percentage: 17.73%
Insider Trades by Quarter for Athersys (NASDAQ:ATHX)
Institutional Ownership by Quarter for Athersys (NASDAQ:ATHX)
Insider Trades by Quarter for Athersys (NASDAQ:ATHX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/16/2017John J HarringtonEVPSell36,000$1.45$52,200.00View SEC Filing  
2/1/2017Ismail KolaDirectorBuy15,000$1.01$15,150.00View SEC Filing  
2/1/2017Laura K CampbellInsiderBuy20,000$1.01$20,200.00View SEC Filing  
12/19/2016William Lehmann JrInsiderSell3,000$1.60$4,800.00View SEC Filing  
12/16/2016John J HarringtonEVPSell15,000$1.60$24,000.00View SEC Filing  
9/19/2016William Lehmann JrInsiderSell3,000$1.96$5,880.00View SEC Filing  
9/16/2016John J HarringtonEVPSell15,000$1.96$29,400.00View SEC Filing  
6/21/2016William Lehmann JrCOOSell25,000$2.17$54,250.00View SEC Filing  
3/21/2016William Lehmann JrCOOSell25,000$2.41$60,250.00View SEC Filing  
12/21/2015William Lehmann, Jr.COOSell25,000$1.03$25,750.00View SEC Filing  
9/21/2015Bokkelen Gil VanCEOSell9,500$1.36$12,920.00View SEC Filing  
9/21/2015John J. HarringtonEVPSell8,150$1.36$11,084.00View SEC Filing  
9/21/2015William Lehmann, Jr.COOSell25,000$1.36$34,000.00View SEC Filing  
6/22/2015William Lehmann JrCOOSell25,000$1.21$30,250.00View SEC Filing  
6/19/2015John J HarringtonInsiderSell8,150$1.23$10,024.50View SEC Filing  
6/19/2015Robert J DeansEVPSell5,080$1.23$6,248.40View SEC Filing  
6/9/2015Kenneth H TraubDirectorBuy30,000$1.27$38,100.00View SEC Filing  
3/20/2015William Lehmann JrCOOSell25,000$3.14$78,500.00View SEC Filing  
3/19/2015Bokkelen Gil VanCEOSell9,500$3.10$29,450.00View SEC Filing  
3/19/2015Robert J DeansEVPSell5,080$3.10$15,748.00View SEC Filing  
12/19/2014Bokkelen Gil VanCEOSell9,500$1.29$12,255.00View SEC Filing  
12/19/2014Robert J DeansEVPSell5,080$1.28$6,502.40View SEC Filing  
12/19/2014William Lehmann JrCOOSell30,000$1.29$38,700.00View SEC Filing  
9/24/2014Kenneth H TraubDirectorBuy30,000$1.39$41,700.00View SEC Filing  
9/22/2014William Lehmann JrCOOSell30,000$1.40$42,000.00View SEC Filing  
9/19/2014Bokkelen Gil VanCEOSell9,500$1.41$13,395.00View SEC Filing  
9/19/2014John J HarringtonInsiderSell8,150$1.41$11,491.50View SEC Filing  
9/19/2014Robert J DeansEVPSell5,080$1.41$7,162.80View SEC Filing  
8/18/2014Lorin RandallDirectorSell15,000$1.54$23,100.00View SEC Filing  
6/20/2014William Lehmann JrCOOSell12,000$1.58$18,960.00View SEC Filing  
6/19/2014Bokkelen Gil VanCEOSell9,500$1.63$15,485.00View SEC Filing  
6/19/2014John J HarringtonInsiderSell8,150$1.63$13,284.50View SEC Filing  
6/19/2014Robert J DeansEVPSell5,080$1.63$8,280.40View SEC Filing  
6/19/2014William Lehmann JrCOOSell13,000$1.62$21,060.00View SEC Filing  
3/20/2014William Lehmann JrCOOSell25,000$3.62$90,500.00View SEC Filing  
3/18/2014Bokkelen Gil VanCEOSell9,500$3.54$33,630.00View SEC Filing  
3/18/2014John J HarringtonInsiderSell8,150$3.54$28,851.00View SEC Filing  
3/18/2014Robert J DeansEVPSell5,080$3.54$17,983.20View SEC Filing  
12/20/2013William Lehmann JrCOOSell25,000$2.13$53,250.00View SEC Filing  
12/11/2013Kenneth H TraubDirectorBuy20,000$1.94$38,800.00View SEC Filing  
9/20/2013John J HarringtonInsiderSell30,000$1.82$54,600.00View SEC Filing  
9/20/2013William Lehmann JrCOOSell12,000$1.83$21,960.00View SEC Filing  
11/28/2012Laura K CampbellVPBuy10,000$1.01$10,100.00View SEC Filing  
11/15/2012Robert J DeansEVPBuy3,500$0.99$3,465.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Athersys (NASDAQ:ATHX)
Latest Headlines for Athersys (NASDAQ:ATHX)
Source:
DateHeadline
seekingalpha.com logoAthersys And Aurinia Target Human And Animal Health - Seeking Alpha
seekingalpha.com - June 27 at 3:50 PM
americanbankingnews.com logo Athersys, Inc. (ATHX) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - June 23 at 8:56 AM
americanbankingnews.com logoAthersys, Inc. (ATHX) EVP John J. Harrington Sells 36,000 Shares
www.americanbankingnews.com - June 19 at 7:57 PM
nasdaq.com logoWhy Athersys, Inc. (ATHX) Could Be Positioned for a Surge - Nasdaq
www.nasdaq.com - June 9 at 2:28 AM
finance.yahoo.com logoWhy Athersys, Inc. (ATHX) Could Be Positioned for a Surge
finance.yahoo.com - June 8 at 4:24 PM
americanbankingnews.com logoZacks: Athersys, Inc. (ATHX) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - June 8 at 8:16 AM
seekingalpha.com logoUpcoming Short- And Long-Term Catalysts For Athersys - Seeking Alpha
seekingalpha.com - May 31 at 3:41 PM
americanbankingnews.com logoZacks: Athersys, Inc. (ATHX) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - May 24 at 4:30 PM
americanbankingnews.com logoMaxim Group Reiterates $9.00 Price Target for Athersys, Inc. (ATHX)
www.americanbankingnews.com - May 17 at 7:10 PM
seekingalpha.com logoAthersys Poised For Lucrative Stem Cell Stroke Partnership This Year
seekingalpha.com - May 16 at 12:30 PM
finance.yahoo.com logoETFs with exposure to Athersys, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 4:11 PM
americanbankingnews.com logoAthersys, Inc. (ATHX) Given "Buy" Rating at Maxim Group
www.americanbankingnews.com - May 14 at 4:00 PM
finance.yahoo.com logoAthersys, Inc. :ATHX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 4:14 PM
americanbankingnews.com logoAthersys, Inc. (ATHX) to Post Q2 2017 Earnings of ($0.06) Per Share, William Blair Forecasts
www.americanbankingnews.com - May 12 at 10:40 AM
seekingalpha.com logoAthersys beats by $0.01, beats on revenue
seekingalpha.com - May 11 at 9:11 PM
americanbankingnews.com logoEquities Analysts Issue Forecasts for Athersys, Inc.'s FY2019 Earnings (ATHX)
www.americanbankingnews.com - May 11 at 3:20 PM
finance.yahoo.com logoEdited Transcript of ATHX earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 8:55 PM
americanbankingnews.com logoAthersys, Inc. (ATHX) Posts Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 9 at 9:42 PM
finance.yahoo.com logoAthersys Reports First Quarter 2017 Results
finance.yahoo.com - May 9 at 8:44 PM
americanbankingnews.com logoAthersys, Inc. (ATHX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 9 at 4:38 PM
finance.yahoo.com logoAthersys, Inc. (ATHX)
finance.yahoo.com - May 8 at 8:38 PM
americanbankingnews.com logoAthersys, Inc. (ATHX) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:12 AM
americanbankingnews.com logo Analysts Set $9.00 Target Price for Athersys, Inc. (ATHX)
www.americanbankingnews.com - May 5 at 9:18 AM
americanbankingnews.com logoAthersys (ATHX) Given Daily Coverage Optimism Score of 0.03
www.americanbankingnews.com - May 4 at 4:22 PM
americanbankingnews.com logoAthersys (ATHX) Earning Positive Media Coverage, Report Shows
www.americanbankingnews.com - May 1 at 12:38 PM
americanbankingnews.com logoShort Interest in Athersys, Inc. (ATHX) Grows By 129.9%
www.americanbankingnews.com - April 27 at 7:06 AM
americanbankingnews.com logoAthersys (ATHX) Earns Daily Coverage Optimism Score of 0.22
www.americanbankingnews.com - April 26 at 4:52 PM
americanbankingnews.com logoAthersys (ATHX) Given Daily News Sentiment Rating of 0.17
www.americanbankingnews.com - April 23 at 10:16 AM
americanbankingnews.com logo Athersys, Inc. (ATHX) Given $9.00 Average Target Price by Analysts
www.americanbankingnews.com - April 20 at 11:25 AM
americanbankingnews.com logoAthersys (ATHX) Given News Sentiment Rating of 0.16
www.americanbankingnews.com - April 20 at 8:29 AM
seekingalpha.com logoAthersys: Initiating Coverage With Buy Rating And Price Target Of $8
seekingalpha.com - April 19 at 4:00 PM
americanbankingnews.com logoShort Interest in Athersys, Inc. (ATHX) Decreases By 11.4%
www.americanbankingnews.com - April 18 at 12:54 PM
americanbankingnews.com logoAthersys (ATHX) Earns Daily News Sentiment Rating of 0.24
www.americanbankingnews.com - April 17 at 4:04 PM
finance.yahoo.com logoAthersys to Host First Quarter Financial Results Call
finance.yahoo.com - April 10 at 3:40 PM
americanbankingnews.com logoZacks: Analysts Set $9.00 Price Target for Athersys, Inc. (ATHX)
www.americanbankingnews.com - April 5 at 9:31 AM
americanbankingnews.com logoWilliam Blair Reaffirms "Outperform" Rating for Athersys, Inc. (ATHX)
www.americanbankingnews.com - April 3 at 8:32 AM
fool.com logoHere's What Might Be Pushing Up Shares of Athersys, Inc. Today
www.fool.com - March 31 at 3:49 PM
finance.yahoo.com logoCan the Rally in Athersys (ATHX) Shares Continue?
finance.yahoo.com - March 31 at 3:49 PM
americanbankingnews.com logoAthersys, Inc. (ATHX) to Post Q1 2017 Earnings of ($0.07) Per Share, William Blair Forecasts
www.americanbankingnews.com - March 31 at 12:05 PM
finance.yahoo.com logoIs the Options Market Predicting a Spike in Athersys (ATHX) Stock?
finance.yahoo.com - March 30 at 4:07 PM
finance.yahoo.com logoTonix Pharmaceuticals and Athersys Advance as FDA Clinical Trials Move Forward
finance.yahoo.com - March 30 at 4:07 PM
finance.yahoo.com logoAthersys to Present at Needham Healthcare Conference on April 4
finance.yahoo.com - March 29 at 8:53 PM
investopedia.com logoAthersys (ATHX) Stock Rallies as William Blair Initiates Coverage
www.investopedia.com - March 29 at 8:53 PM
americanbankingnews.com logoAthersys, Inc. (ATHX) Now Covered by Analysts at William Blair
www.americanbankingnews.com - March 28 at 6:42 PM
americanbankingnews.com logoAthersys, Inc. (ATHX) Given a $9.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - March 21 at 3:40 PM
americanbankingnews.com logoBrokerages Expect Athersys, Inc. (ATHX) to Post ($0.06) EPS
www.americanbankingnews.com - March 21 at 11:52 AM
streetinsider.com logoAthersys (ATHX) Says Two Publications Highlight MultiStem for Treating Ischemic Stroke
www.streetinsider.com - March 20 at 8:53 AM
us.rd.yahoo.com logoTwo New Publications Highlight the Potential for MultiStem® Treatment of Ischemic Stroke
us.rd.yahoo.com - March 20 at 8:53 AM
us.rd.yahoo.com logo6:31 am Athersys announces that clinical investigators have published results from Athersys' Phase 2 trial of MultiStem cell therapy for treating ischemic stroke patients in the peer-reviewed journal The Lancet Neurology
us.rd.yahoo.com - March 20 at 8:53 AM
finance.yahoo.com logoATHERSYS, INC / NEW Financials
finance.yahoo.com - March 16 at 5:09 PM

Social

Chart

Athersys (ATHX) Chart for Thursday, June, 29, 2017

This page was last updated on 6/29/2017 by MarketBeat.com Staff